We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Sarepta Therapeutics Securities Class Action Gets The Boot

Law360, New York (April 1, 2015, 5:07 PM EDT) -- A Massachusetts federal judge on Tuesday tossed a proposed putative securities class action accusing Sarepta Therapeutics Inc. of misleading investors over the chances of its muscular dystrophy drug eteplirsen hitting the market, saying that the biopharma company couched its optimistic statements with proper disclosures.

The complaint had pointed to statements about the strength of U.S. Food and Drug Administration trials for the drug as misleading because the trials utilized a population of only 10 to 12 patients and held up statements about a purported benefit of the...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Corban v. Sarepta Therapeutics, Inc. et al


Case Number

1:14-cv-10201

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Indira Talwani

Date Filed

January 27, 2014

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.